VA
JBIO

VR Adviser’s Jade Biosciences JBIO Stock Holding History

VR Adviser’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.2M Hold
3,220,364
– – 1.69% 17
2025
Q4 		$49.7M Hold
3,220,364
– – 2.45% 12
2025
Q3 		$27.8M Hold
3,220,364
– – 1.56% 19
2025
Q2 		$32.2M Buy
+3,220,364
New +$110M 2.41% 12
2023
Q2 		– Sell
-23,826
Closed -$16.8M – 32
2023
Q1 		$16.8M Buy
23,826
+2,458
+12% +$2.04M 3.28% 12
2022
Q4 		$21.9M Sell
21,368
-2,458
-10% -$1.78M 3.69% 9
2022
Q3 		$13.8M Buy
23,826
+6,957
+41% +$4.64M 2.13% 16
2022
Q2 		$9.23M Buy
16,869
+12,554
+291% +$6M 1.82% 16
2022
Q1 		$2.77M Buy
+4,315
New +$1.67M 0.45% 26

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

VR Adviser's JBIO Position: Q1 2026 in Review

VR Adviser held its Jade Biosciences (JBIO) position steady in Q1 2026 at 3,220,364 shares worth $45.2M. The position accounts for 1.69% of the portfolio, ranked #17.

VR Adviser first reported a position in JBIO in Q1 2022 and has held it in 9 quarters since. The position peaked at $49.7M in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • VR Adviser held 3,220,364 shares of Jade Biosciences worth $45.2M as of Q1 2026.
  • VR Adviser left its Jade Biosciences share count unchanged in Q1 2026.
  • Jade Biosciences made up 1.69% of VR Adviser's portfolio in Q1 2026, its #17 holding.
  • VR Adviser first reported a position in Jade Biosciences in Q1 2022 and has held it in 9 quarters since.
  • VR Adviser's Jade Biosciences position peaked at $49.7M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.